Project Grant HT94252410086

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $808,866 to Progenra Inc., a biotechnology firm located in Malvern, Pennsylvania. The funding supports research to evaluate novel small molecule compounds that activate the ubiquitin proteasome system (UPS) as potential therapeutics for treating acute and chronic pancreatitis. Key objectives include assessing...

This federal Project Grant award of $161,695 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research on the role of purinergic signaling in intestinal inflammation and wound healing. The principal objective is to elucidate how the purinergic receptor P2Y1 expressed in intestinal epithelial cells influences the inflammatory response and repair processes during colitis. The research...

This Project Grant award of $1,170,271 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research program) aims to investigate the mechanisms by which the X-box binding protein 1 (XBP1) pathway regulates bile acid metabolism during cholestatic liver disorders. The central hypothesis is that hepatic XBP1 activation reduces bile acid synthesis and regulates bile acid metabolism by transcriptionally...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $169,388 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of California, Irvine (UCI). The purpose of this 5-year grant, awarded on September 9, 2025, is to explore the role of the enzyme fatty acid amide hydrolase (FAAH) and its regulation of endocannabinoid signaling as a novel, opiate-sparing therapeutic target for managing pain...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is providing $1,060,675 to the University of Arizona to study the impact of the absent in melanoma 2 (AIM2) protein on intestinal stem cell differentiation during inflammation. The research aims to elucidate the molecular and cellular processes by which AIM2 regulates the development of...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $164,700 to the University of California, Davis to investigate the mechanosensitive regulation of intestinal smooth muscle cell calcium signaling during gut development. The overarching goal is to improve understanding of the underlying mechanisms contributing to prematurity-related...

This Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the MRGPRX4 receptor in mediating bile acid-induced activation and sensitization of esophageal nociceptive C-fibers. The $565,338 award will support a 5-year research project at The Johns Hopkins University to characterize the expression of MRGPRX4 in...

This $852,465 Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research at the University of Chicago to investigate the role of pancreatic elastase in beta cell health, autoimmunity, and type 1 diabetes. The project aims to unravel the molecular crosstalk between the exocrine and endocrine pancreas, with a focus on how...

This $370,575 project grant from the National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research at the University of Cincinnati investigating the molecular mechanisms of growth in pancreatic cancer with GNAS mutations. The grant supports studies from August 1, 2022 to July 31, 2027 to further the understanding of the oncogenic functions of mutant GNAS and its downstream signaling pathways. Specifically, the research will illuminate...

This federal Project Grant award of $151,643 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research by Dr. Ornelas Sanchez at the University of Colorado-Denver to investigate the use of proteolysis targeting chimeras (PROTACs) to regulate hypoxia-inducible factors (HIFs) and their potential therapeutic applications for inflammatory bowel disease (IBD)....